Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19.

Victoria KauerDavid TotschnigFerdinand WaldenbergerMax AugustinMario KarolyiMichelle NägeliChristoph WenischAlexander Zoufaly

Published in: Viruses (2023)

All antiviral treatment options effectively prevented hospitalization in high-risk COVID-19 patients and were well tolerated. Side effects were pronounced in patients with N/R.

Keyphrases

sars cov
coronavirus disease
open label
respiratory syndrome coronavirus
early onset
placebo controlled
randomized controlled trial